Role of cannabinoids in the development of fatty liver (steatosis) - Wikidata - awgldk - TriplyDB

Role of cannabinoids in the development of fatty liver (steatosis)

Role of cannabinoids in the development of fatty liver (steatosis)

http://www.wikidata.org/entity/Q33749478

about

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake The role of endocannabinoids system in fatty liver disease and therapeutic potentials Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias.FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.Endocannabinoid tone versus constitutive activity of cannabinoid receptors.L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function.Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol.Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.Immunohistochemical analysis of cannabinoid receptor 1 expression in steatotic rat livers.Cannabis in sport: anti-doping perspective.Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.Mitochondrial carnitine palmitoyl transferase-II inactivity aggravates lipid accumulation in rat hepatocarcinogenesis.Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.Loss of fatty acid binding protein-1 alters the hepatic endocannabinoid system response to a high-fat diet.Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model.Δ9-Tetrahydrocannabinol Induces Endocannabinoid Accumulation in Mouse Hepatocytes: Antagonism by Fabp1 Gene Ablation.Action of the chemical agent fipronil (active ingredient of acaricide Frontline®) on the liver of mice: an ultrastructural analysis.Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells.Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease.Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits

P2860

Q26850858-2A64DF03-C57C-40E4-A97E-6D6459D860A7 Q27009466-F8554CD0-E467-4CEA-9A28-53499CD66F8B Q33613330-D8115224-A7F7-4013-B553-228FCE601909 Q34538205-3E32DE4B-03E7-412F-B7C5-15547FC5D4C3 Q35193265-1F5D68C4-88DF-4A0C-AC78-5EDBFE6E4574 Q35580023-72BFC573-3448-45E2-878E-4B09946F40F3 Q35895832-1B7FCB99-5D60-4E46-87D1-6DF7733247CA Q36026554-8DD988E0-3778-4867-A734-8F7A8F8D86EF Q36742010-ED00AB4E-3D43-4E24-AC59-C81EC88C7C3F Q37029485-88409D23-9D72-4C3F-8C34-1D408EEE9A0C Q38503842-F36DCCA6-91E6-4250-9B09-F3980F89140E Q38939502-AC1B718D-DB81-42B9-806B-1184401C9D8F Q41969545-AD93D0CC-9A51-49BC-B03C-1A2959071AA7 Q45064430-8CB31813-0A8B-4F98-9E10-F40107CBAAFA Q47621729-65C5C3B7-745F-480A-80CE-14A998473FB2 Q48018603-FB6EE74E-53FE-40C4-9F3D-068BD70570E2 Q50134192-DDEACAE9-FA8C-4783-A428-103FD0857AB1 Q52724523-C8D87D5C-46C2-4890-8020-5F72DFF522E1 Q55282555-942C8A53-EDED-4A7F-950D-F73FE83BC758 Q55452630-3F8529A2-C761-4AA1-9108-E3D5DF80E2CD Q58753073-C49C8C7A-1AA7-46B4-B53B-14D68DC08FBA Q58776750-BFC021C7-6EF4-48E3-9783-F5F9E296F24E

P2860

Role of cannabinoids in the development of fatty liver (steatosis)

http://www.wikidata.org/entity/Q33749478

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Role of cannabinoids in the development of fatty liver (steatosis)

@ast

Role of cannabinoids in the development of fatty liver (steatosis)

@en

type

label

Role of cannabinoids in the development of fatty liver (steatosis)

@ast

Role of cannabinoids in the development of fatty liver (steatosis)

@en

prefLabel

Role of cannabinoids in the development of fatty liver (steatosis)

@ast

Role of cannabinoids in the development of fatty liver (steatosis)

@en

P1433

Q33749478-A51C4170-31E9-4E65-AA8A-F103A7FF2704

P1476

Q33749478-79005ED6-0BA7-4301-BC10-20030D83FC9C

P2093

Q33749478-3C362E35-E659-4C00-9A0C-8395F602DF9C

Q33749478-9C14AD37-55E5-446D-B670-144C559C469E

Q33749478-DC9382E0-7E62-4D1C-999A-2C5593F7A2F6

P2860

Q33749478-089A8095-84BF-40FB-A0E0-5B525B6A64F3

Q33749478-24519799-3B3C-47FC-B3E1-B316B7B98879

Q33749478-25A38493-392A-4C7C-9B30-A9F08221B7CC

Q33749478-3FC5FD77-AEFC-4551-84CD-89D39FF8AA08

Q33749478-402BAF68-D7B0-4A19-8CE4-EEA96CE00CCA

Q33749478-56775594-1EFB-43BB-AD0C-038408E06266

Q33749478-56E6CD8E-137D-4BA3-B52E-80F9DDC0935C

Q33749478-6E1DF1E7-7C0A-4533-8025-C3EF93122DD7

Q33749478-7438C2DB-46D3-4F46-81E9-D6B507DC7DAF

Q33749478-7894F03D-0091-4A84-A60A-28CB1FD864D9

P2888

Q33749478-B6E3BE57-0203-4C84-A46D-4413B47E558D

P304

Q33749478-F1C4CA87-4556-48F5-8A0D-D3E455FDB3D9

P31

Q33749478-D0205F3F-20AB-41F4-836D-EC8D7D01401D

P356

Q33749478-110C2EF6-41CB-44B1-A9EA-549B3CEDD5AD

P407

Q33749478-C4C86DA8-45FA-4444-9102-76423809CDE7

P433

Q33749478-5185BE2D-7549-4318-B1C1-A039C2BB15F3

P478

Q33749478-0D543C78-B503-4C37-A326-391DD2096A4E

P577

Q33749478-9B8A7741-A220-415B-A912-87DF48A82D01

P5875

Q33749478-C1DA978E-6DEA-4D96-8366-F3D9C7849730

P6179

Q33749478-E945AD7F-4C36-473D-8A4E-745B66DE06DC

P698

Q33749478-1A556B46-B013-450D-B186-5BBE8214A0C2

P921

Q33749478-EED61146-942C-48F0-A4F7-E14849E89443

P932

Q33749478-04EDFA9E-7D26-4DDC-B114-C82ECF2060F1

P356

S12248-010-9178-0

P1433

The AAPS Journal

P1476

Role of cannabinoids in the development of fatty liver (steatosis)

@en

P2093

David Shurtleff

http://www.w3.org/2001/XMLSchema#string

Rao Rapaka

http://www.w3.org/2001/XMLSchema#string

Vishnudutt Purohit

http://www.w3.org/2001/XMLSchema#string

P2860

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

The endocannabinoid system as an emerging target of pharmacotherapy

Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity

Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data.

Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis

Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins.

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

Molecular mechanisms of alcoholic fatty liver

Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets.

Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis.

P2888

s12248-010-9178-0

P304

233-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-010-9178-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41762047

http://www.w3.org/2001/XMLSchema#string

P6179

1037726315

http://www.w3.org/2001/XMLSchema#string

P698

20204561

http://www.w3.org/2001/XMLSchema#string

P921

P932

2844512

http://www.w3.org/2001/XMLSchema#string